13 active not recruiting. 13 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 13 |
| Phase 1 | 3 | Active not recruiting 3 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome BAY 3401016, Placebo - Alport Syndrome | Phase 2 | Active not recruiting | Bayer | 60 | 2025-11-19 | 2026-10-29 |
| A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy RG002C0106, placebo subcutaneous administration - IgA Nephropathy (IgAN) | Phase 2 | Active not recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 30 | 2025-09-08 | 2026-10-13 |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) CC-97540, Fludarabine, Cyclophosphamide - Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 | Active not recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 89 | 2025-07-14 | 2026-08-03 |
| A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases SGB-9768 - IgA Nephropathy (IgAN), C3 Glomerulopathy | Phase 2 | Active not recruiting | Suzhou Sanegene Bio Inc. | 45 | 2025-06-06 | 2026-09-04 |
| Monthly Dosing of Atacicept in IgAN Atacicept - IgA Nephropathy (IgAN), Berger Disease | Phase 2 | Active not recruiting | Vera Therapeutics, Inc. | 90 | 2025-05-29 | 2026-04-13 |
| Phase 2b Open-Label Repeat Kidney Biopsy Study Sibeprenlimab - IgA Nephropathy | Phase 2 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 56 | 2024-12-05 | 2026-10-27 |
| A Clinical Trial With KJ103 in Anti-GBM Disease KJ103 for Injection, Cyclophosphamide, Glucocorticoids - Anti-Glomerular Basement Membrane Disease | Phase 2 | Active not recruiting | Shanghai Bao Pharmaceuticals Co., Ltd. | 12 | 2024-10-21 | 2025-06-13 |
| A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) rapcabtagene autoleucel - Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 179 | 2024-09-04 | 2026-09-02 |
| An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Povetacicept - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 1 / Phase 2 | Active not recruiting | Alpine Immune Sciences, Inc. | 72 | 2023-03-15 | 2026-10-20 |
| Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis Recombinant Humanized Monoclonal Antibody MIL62 Injection, placebo - Lupus Nephritis | Phase 1 / Phase 2 | Active not recruiting | Beijing Mabworks Biotech Co., Ltd. | 41 | 2021-11-26 | 2025-07-02 |
| Daratumumab to Treat Active Lupus Nephritis Daratumumab - Lupus Nephritis | Phase 2 | Active not recruiting | Mayo Clinic | 12 | 2021-04-20 | 2026-10-07 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
Glomerulonephritis, IGA (6) · Lupus Nephritis (6) · Lupus Erythematosus, Systemic (3) · Nephritis, Hereditary (2) · Anti-Glomerular Basement Membrane Disease (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Churg-Strauss Syndrome (1) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · Granulomatosis with Polyangiitis (1) · Microscopic Polyangiitis (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Kidney Diseases (13) · Male Urogenital Diseases (13) · Urogenital Diseases (13) · Urologic Diseases (13) · Autoimmune Diseases (12) · Glomerulonephritis (12) · Immune System Diseases (12) · Connective Tissue Diseases (8) · Skin and Connective Tissue Diseases (8) · Lupus Erythematosus, Systemic (3) · Collagen Diseases (2) · Congenital Abnormalities (2)
Cyclophosphamide (2) · Atrasentan (1) · Glucocorticoids (1) · Injections (1) · Plasma Exchange (1) · TACI receptor-IgG Fc fragment fusion protein (1) · Tablets (1) · dapagliflozin (1) · daratumumab (1) · fludarabine (1)
Novartis Pharmaceuticals (2) · Alpine Immune Sciences, Inc. (1) · Bayer (1) · Beijing Mabworks Biotech Co., Ltd. (1) · Hospital Civil Juan I. Menchaca (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · Mayo Clinic (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (1) · Shanghai Bao Pharmaceuticals Co., Ltd. (1) · Suzhou Sanegene Bio Inc. (1) · Vera Therapeutics, Inc. (1)
United States (8) · China (5) · United Kingdom (5) · Argentina (4) · Italy (4) · Japan (4) · South Korea (4) · Spain (4) · Australia (3) · Canada (3) · France (3) · Germany (3) · Poland (3) · Austria (2) · Brazil (2)
Fernando Fervenza, MD (1) · Zeeshan Khawaja (1)
PMID 37254256, PMID 39899371, PMID 40938675, PMID 41442197
2023 (1)